BioVaxys Technology Corp. Lifts Management Cease Trade Order and Completes Debt Settlement
April 11, 2025 - 10:13
BioVaxys Technology Corp. has officially announced the revocation of the management cease trade order that had been in place, signaling a positive shift for the company. This development comes alongside the successful closure of a debt settlement transaction, which is expected to enhance the company's financial standing.
The revocation of the cease trade order allows for the resumption of regular trading activities, providing shareholders with renewed confidence in the company's operations. This decision reflects the management's commitment to transparency and compliance with regulatory requirements.
In conjunction with this announcement, the completion of the debt settlement transaction marks a significant step in BioVaxys's strategic financial management. By addressing outstanding debts, the company aims to streamline its financial obligations and focus on its core business objectives.
Overall, these developments are poised to bolster BioVaxys's position in the biotechnology sector, paving the way for future growth and innovation.
MORE NEWS
August 9, 2026 - 18:31
County agenda features tax, technology and fairgroundsThe meeting will center on how to fund the ongoing fairgrounds project, a long-discussed priority for the county. Officials are expected to review the latest cost estimates and possible revenue...
August 9, 2026 - 00:24
‘AI slop’ crackdown: LinkedIn, Snap target low-quality gen-AI contentSocial platforms are starting to push back against the flood of generic, machine-generated posts, but they are doing so carefully. LinkedIn and Snap have both announced new measures aimed at...
August 8, 2026 - 05:47
Why GigaCloud Technology (GCT) Is Up 21.7% After Strong Q2 Results And New Buyback PlanGigaCloud Technology saw its stock surge 21.7% in early trading following the release of its second-quarter financial results and the announcement of a new capital return program. The company...
August 7, 2026 - 22:40
As FDA Approves First-Ever mRNA Flu Vaccine For Older Adults, Past KFF Polling Showed Most In This Age Group Were Uncertain About the Technology’s SafetyOn August 5, 2026, the U.S. Food and Drug Administration gave the green light to the first messenger RNA flu vaccine for adults aged 50 and older. The decision came after a clinical trial involving...